MedTrace Logo

Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor

NCT00685828 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 946

Last updated 2014-07-04

No results posted yet for this study

Summary

RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which dose of imatinib mesylate is more effective in treating gastrointestinal stromal tumor.

PURPOSE: This randomized phase III trial is studying two different doses of imatinib mesylate to compare how well they work in treating patients with unresectable or metastatic gastrointestinal stromal tumor.

Conditions

  • Gastrointestinal Stromal Tumor

Interventions

DRUG

imatinib mesylate

By mouth

Sponsors & Collaborators

  • Italian Sarcoma Group

    collaborator NETWORK

  • Australasian Gastro-Intestinal Trials Group

    collaborator NETWORK

  • Scandinavian Sarcoma Group

    collaborator OTHER

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • Jacob Verweij, MD, PhD · Daniel Den Hoed Cancer Center at Erasmus Medical Center

  • Paolo G. Casali, MD · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

  • John R. Zalcberg, MB, BS, PhD, FRACP · Peter MacCallum Cancer Centre, Australia

  • Kirsten Sundby Hall, MD · Lund University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-31
Primary Completion
2002-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00685828 on ClinicalTrials.gov